Leyden Labs

Last Friday, the Leyden Labs team applied their problem-solving and collaborative mindset during a wonderful afternoon of team building. Navigating climbing routes and kayaking through the waters culminated in a wonderful team dinner. It’s a pleasure to enjoy taking some time for fun with work colleagues – despite the Dutch weather! #team #biotech

Milad Tannazi, Business Development Manager at Leyden Labs, looks forward to attending the Dutch Biotech Event by hollandbio today in Maarssen. It's always a great opportunity to connect with others in the Dutch biotech community!

As a biotech scale-up company, we are proud to be based in the Netherlands. Deep-tech companies drive technological innovation and are instrumental for economic growth. With 9 other tech scale-ups spanning various industries, we strongly believe more should and can be done to ensure more successful start- and scale-up companies in the Netherlands. Let’s build the 10 ASMLs of tomorrow! 📌 Read more in today's FD article here: https://lnkd.in/eR9NGUec 📌 For more information, see: www.techchampions.nl SMART Photonics Battolyser Systems Nicolab Nearfield Instruments Cradle LeydenJar Axelera AI EclecticIQ QuantWare

The opinion that we are underprepared for an avian flu pandemic is reflected in 2 New York Times articles published this week (links in comments): *It’s unclear if we have the right tools to fight a human H5 pandemic. It is uncertain if the (limited) stockpile of influenza antivirals will be effective against the actual pandemic strain. Vaccine development efforts have started, but finalizing a vaccine, and manufacturing and distributing sufficient quantities will still present challenges. *Cats are getting sick from H5N1 after drinking raw (unpasteurized) milk of infected cows or preying on infected birds, with a 67% mortality rate among felines – reiterating that dairy products pose a threat if not properly treated to mitigate risk. While part of the influenza pandemic preparedness strategy can be to do more of what we already know (i.e., vaccines and antivirals), it should be complemented by innovation. The prophylactic intranasal spray we have in development to protect against influenza may enable public health to add something new to the toolbox of preparedness. #influenza #pandemicpreparedness #avianflu

Are governments underprepared for an #influenza #pandemic? Rick Bright, PhD, former Director of BARDA, commented in a recent interview with BioCentury Inc. (The BioCentury Show) that the US government “does not have support to fund the things that need to be funded to modernize our approach and response capabilities, so we have a dynamic readiness position and posture for pandemic influenza.” At Leyden Labs, we are advancing products that we expect to provide novel solutions for rapid response and broad reach of protection in the face of exactly such a threat. https://lnkd.in/e27nieu2

While summer is not typically a time for focus on #influenza, this year will be different. The US Centers for Disease Control and Prevention have announced an Enhanced Summer 2024 Influenza Surveillance program due to the pervasive concern for #avianflu. While efforts are also underway to protect the food supply and ensure animal health, the goal of this initiative is specifically to monitor spread of H5 to people and to reduce human exposure to infected animals. Read more here: https://lnkd.in/eSKt2Rfn

As the traditional cold/flu season comes to an end in the Northern Hemisphere, let’s look back on the impact influenza has had this year. In the US, less than 50% of the population received the flu vaccine, which is lower than generally observed, particularly among children. Preliminarily, Centers for Disease Control and Prevention estimated vaccine effectiveness for the 2023-2024 season to be 52% to 67% in children, and as low as 33% in adults. The impact is revealed in the in-season preliminary estimates of the burden of influenza reported by the CDC shown in the graphic below. While these values remain to be confirmed with time, this burden of illness is higher than pre-pandemic (2018-2019) levels. That trend paired with declining vaccination rates are cause for concern. At Leyden Labs, we believe it is important to stay vigilant and maintain protective measures against influenza and other concerning respiratory viruses. Meanwhile, we continue to work at full speed on new approaches to influenza protection. #influenza #infection #burdenofillness

Concern for highly pathogenic avian influenza is going up with the 2nd human case reported in the US and the 1st human case reported in Australia this week. We are working day and night on the development of our broadly protective influenza antibody, CR9114, which showed in vitro and in vivo that it could protect against these #AvianFlu strains. It would be a critical tool against an avian flu outbreak - to protect broadly with intranasal administration. Read more in our paper here: https://bit.ly/48laZdF

We were honored to host a visit on Tuesday from His Majesty King Carl XVI Gustaf of Sweden, with a delegation from the Royal Swedish Academy of Engineering Sciences. As part of the visit to the Leiden Bio Science Park, we had the unique opportunity to showcase Leyden Labs’ mission, groundbreaking mucosal technology and our top-of-the-line laboratories. At Leyden Labs, we feel very privileged to have had this opportunity. #biotechnology #mucosal_immunity #leiden #iva1919

We are looking forward to attending Bio€quity Europe next week in San Sebastián, Spain. This conference is a great opportunity in Europe to connect with and learn from others doing amazing work throughout the biotech industry. https://lnkd.in/dzunkQc #biotech #bioequity